Search

Your search keyword '"Kim, Uh Jin"' showing total 4 results
Start Over Author "Kim, Uh Jin" Journal antiviral therapy
4 results on '"Kim, Uh Jin"'

3. Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-a for Middle East Respiratory Syndrome

Author

Kim, Uh Jin, Won, Eun-Jeong, Kee, Seung-Jung, Jung, Sook-In, and Jang, Hee-Chang

Abstract

Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-a has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.

Published
2016
Full Text
View/download PDF

4. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.

Author

Kim UJ, Won EJ, Kee SJ, Jung SI, and Jang HC

Subjects
Coronavirus Infections diagnostic imaging, Coronavirus Infections virology, Drug Therapy, Combination, Humans, Interferon-alpha administration & dosage, Lopinavir administration & dosage, Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus drug effects, Middle East Respiratory Syndrome Coronavirus genetics, Middle East Respiratory Syndrome Coronavirus isolation & purification, Republic of Korea, Ribavirin administration & dosage, Ritonavir administration & dosage, Antiviral Agents administration & dosage, Coronavirus Infections drug therapy
Abstract

Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results